NOVARTIS | DR. DATSONS LABS | NOVARTIS/ DR. DATSONS LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 562.8 | -10.9 | - | View Chart |
P/BV | x | 31.6 | 0.2 | 19,431.2% | View Chart |
Dividend Yield | % | 1.4 | 0.0 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NOVARTIS Mar-19 |
DR. DATSONS LABS Mar-14 |
NOVARTIS/ DR. DATSONS LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 980 | 126 | 780.3% | |
Low | Rs | 600 | 31 | 1,942.4% | |
Sales per share (Unadj.) | Rs | 198.7 | 133.0 | 149.4% | |
Earnings per share (Unadj.) | Rs | 21.0 | 0.2 | 13,830.1% | |
Cash flow per share (Unadj.) | Rs | 22.3 | 6.6 | 336.8% | |
Dividends per share (Unadj.) | Rs | 10.00 | 0 | - | |
Dividend yield (eoy) | % | 1.3 | 0 | - | |
Book value per share (Unadj.) | Rs | 307.5 | 128.8 | 238.8% | |
Shares outstanding (eoy) | m | 24.69 | 31.66 | 78.0% | |
Bonus/Rights/Conversions | - | FCCB | - | ||
Price / Sales ratio | x | 4.0 | 0.6 | 675.7% | |
Avg P/E ratio | x | 37.7 | 516.1 | 7.3% | |
P/CF ratio (eoy) | x | 35.5 | 11.8 | 299.8% | |
Price / Book Value ratio | x | 2.6 | 0.6 | 422.9% | |
Dividend payout | % | 47.7 | 0 | - | |
Avg Mkt Cap | Rs m | 19,508 | 2,477 | 787.4% | |
No. of employees | `000 | 0.6 | NA | - | |
Total wages/salary | Rs m | 1,171 | 56 | 2,091.3% | |
Avg. sales/employee | Rs Th | 8,445.4 | NM | - | |
Avg. wages/employee | Rs Th | 2,015.7 | NM | - | |
Avg. net profit/employee | Rs Th | 891.0 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 4,907 | 4,211 | 116.5% | |
Other income | Rs m | 783 | 79 | 994.4% | |
Total revenues | Rs m | 5,689 | 4,289 | 132.6% | |
Gross profit | Rs m | 123 | 569 | 21.6% | |
Depreciation | Rs m | 32 | 204 | 15.6% | |
Interest | Rs m | 16 | 430 | 3.7% | |
Profit before tax | Rs m | 858 | 13 | 6,753.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | -2 | 0.0% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 340 | 6 | 5,573.8% | |
Profit after tax | Rs m | 518 | 5 | 10,785.4% | |
Gross profit margin | % | 2.5 | 13.5 | 18.5% | |
Effective tax rate | % | 39.6 | 48.0 | 82.5% | |
Net profit margin | % | 10.6 | 0.1 | 9,254.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 8,055 | 6,852 | 117.6% | |
Current liabilities | Rs m | 1,850 | 6,711 | 27.6% | |
Net working cap to sales | % | 126.4 | 3.3 | 3,775.9% | |
Current ratio | x | 4.4 | 1.0 | 426.4% | |
Inventory Days | Days | 45 | 161 | 28.0% | |
Debtors Days | Days | 34 | 318 | 10.6% | |
Net fixed assets | Rs m | 150 | 3,673 | 4.1% | |
Share capital | Rs m | 123 | 317 | 39.0% | |
"Free" reserves | Rs m | 7,469 | 3,761 | 198.6% | |
Net worth | Rs m | 7,592 | 4,078 | 186.2% | |
Long term debt | Rs m | 0 | 1,671 | 0.0% | |
Total assets | Rs m | 9,824 | 12,633 | 77.8% | |
Interest coverage | x | 54.9 | 1.0 | 5,336.8% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.5 | 0.3 | 149.8% | |
Return on assets | % | 5.4 | 3.4 | 157.7% | |
Return on equity | % | 6.8 | 0.1 | 5,792.7% | |
Return on capital | % | 11.5 | 7.7 | 150.0% | |
Exports to sales | % | 0 | 22.9 | 0.0% | |
Imports to sales | % | 0 | 14.3 | 0.0% | |
Exports (fob) | Rs m | NA | 964 | 0.0% | |
Imports (cif) | Rs m | NA | 602 | 0.0% | |
Fx inflow | Rs m | 58 | 964 | 6.0% | |
Fx outflow | Rs m | 1,326 | 607 | 218.5% | |
Net fx | Rs m | -1,269 | 357 | -355.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -1,943 | 1,345 | -144.5% | |
From Investments | Rs m | 2,742 | -2,256 | -121.6% | |
From Financial Activity | Rs m | -298 | -1,200 | 24.9% | |
Net Cashflow | Rs m | 501 | -2,111 | -23.8% |
Indian Promoters | % | 0.0 | 4.5 | - | |
Foreign collaborators | % | 75.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.0 | 0.0 | - | |
FIIs | % | 1.6 | 1.4 | 118.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 21.5 | 94.1 | 22.8% | |
Shareholders | 41,647 | 20,807 | 200.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare NOVARTIS With: GSK PHARMA ASTRAZENECA PHARMA DIVIS LABORATORIES IPCA LABS NATCO PHARMA
Compare NOVARTIS With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
| |
In addition to the usual stock market updates of the week, I talk about how RBI's monetary policy decision and slowing economy impacts you and your portfolio of stocks.
For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.
More Views on NewsA single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
This one trade had my subscribers laughing all the way to the bank.
Should you invest in growth stocks or value stocks to make strong returns in this market?
The two trends that are playing out as Sensex touches new record high.
Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.
More